Evidence map›Paper›PMID 22234250›Full record

ArticleArchives of biochemistry and biophysics2012

The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1.

Yanlai Lai, Meihua Song, Kevin Hakala, Susan T Weintraub, Yuzuru Shiio

Abstract read
In one paragraph

Article in Archives of biochemistry and biophysics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pathway Analysis of Renal Cell Carcinoma Genome-Wide Association Studies Identifies Novel Associations.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yanlai LaiGreehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX 78229-3900, USA.
Meihua Song
Kevin Hakala
Susan T Weintraub
Yuzuru Shiio
The University of Texas Health Science Center at San Antonio · USThe University of Texas Health Science Center · US

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Analysis of the VHL-HIF hydroxylase pathwayR01CA125020 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SHIIO, YUZURU · 2007 to 2011
$1.1M
NCI NIH HHS CA054174NCI NIH HHS CA125020NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA125020
6 · The paper itself

Abstract

Inactivation of the von Hippel-Lindau (VHL) tumor suppressor is associated with renal carcinoma, hemangioblastoma and pheochromocytoma. The VHL protein is a component of a ubiquitin ligase complex that ubiquitinates and degrades hypoxia inducible factor-α (HIF-α). Degradation of HIF-α by VHL is proposed to suppress tumorigenesis and tumor angiogenesis. Several lines of evidence also suggest important roles for HIF-independent VHL functions in tumor suppression and other biological processes. Using GST-VHL pull-down experiment and mass spectrometry, we detected an interaction between VHL and heterochromatin protein 1 (HP1). We identified a conserved HP1-binding motif (PXVXL) in the β domain of VHL, which is disrupted in a renal carcinoma-associated P81S mutant. We show that the VHL P81S mutant displays reduced binding to HP1, yet retains the ability to interact with elongin B, elongin C, and cullin 2 and is fully capable of degrading HIF-α. We also demonstrate that HP1 increases the chromatin association of VHL. These results suggest a role for the VHL-HP1 interaction in VHL chromatin targeting.

Indexed as

ProteolysisAmino Acid MotifsAmino Acid SubstitutionAnimalsCell LineChromatinChromobox Protein Homolog 5Chromosomal Proteins, Non-HistoneCullin ProteinsElonginHumansHypoxia-Inducible Factor 1, alpha SubunitKidney NeoplasmsMiceMutation, MissenseNeovascularization, PathologicChromatinChromobox Protein Homolog 5Chromosomal Proteins, Non-HistoneCUL2 protein, humanCullin ProteinsELOB protein, humanElob protein, mouseELOC protein, humanEloc protein, mouseElonginHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitTranscription FactorsVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID22234250
PMCPMC3274591
OpenAlexW1967218593

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.